Company Description
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn’s disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease.
It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy.
It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain.
The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
| Country | Australia |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 73 |
| CEO | Silviu Itescu |
Contact Details
Address: 55 Collins Street, Level 38 Melbourne, VIC 3000 Australia | |
| Phone | 61 3 9639 6036 |
| Website | mesoblast.com |
Stock Details
| Ticker Symbol | MESO |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001345099 |
| CUSIP Number | 590717104 |
| ISIN Number | US5907174016 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul J. Simmons BSc, Ph.D. | Scientific Advisor to the Chief Executive Officer |
| Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) | Founder, Chief Executive Officer, MD, Chairman of Scientific Advisory Board and Executive Director |
| Dr. Eric A. Rose M.D. | Chief Medical Officer and Executive Director |
| Andrew Chaponnel B.Com. | Interim Chief Finance Officer |
| Peter T. Howard B.Sc., L.L.B., LLB (Hons) | General Counsel and Corporate Executive |
| Geraldine Storton B.Sc., M.B.A., MMS | Head of Regulatory Affairs and Quality Management |
| Justin Horst B.S. | Head of Manufacturing |
| Dr. Fiona See Ph.D. | Senior Vice President and Head of Translational Research |
| Niva Sivakumar B.Com., L.L.B. | Joint Company Secretary |
| Paul Hughes BPHARM | Joint Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 1, 2024 | 6-K | Report of foreign issuer |
| Oct 18, 2024 | 6-K | Report of foreign issuer |
| Oct 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 1, 2024 | 6-K | Report of foreign issuer |
| Aug 29, 2024 | 6-K | Report of foreign issuer |
| Aug 29, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Aug 1, 2024 | 6-K | Report of foreign issuer |
| Jul 25, 2024 | 6-K | Report of foreign issuer |
| Jul 23, 2024 | 6-K | Report of foreign issuer |
| Jul 11, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |